5-(2-methoxyethyl)-3-[6-(1H-1,2,4-triazol-5-yl)pyridin-3-yl]-7,8-dihydro-6H-pyrazino[2,3-b]pyrazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(2-methoxyethyl)-3-[6-(1H-1,2,4-triazol-5-yl)pyridin-3-yl]-7,8-dihydro-6H-pyrazino[2,3-b]pyrazine
• 化学式: C₁₆H₁₈N₈O
• 分子量: 338.37
• InChiKey: ZQAUGDYYJHTXLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
  申请人：Signal Pharmaceuticals, LLC

  公开号：US10004735B2

  公开（公告）日：2018-06-26

  Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.

  本文提供了治疗或预防癌症的方法，包括向癌症患者施用有效量的 TOR 激酶抑制剂和有效量的第二种活性剂。
• Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US10167290B2

  公开（公告）日：2019-01-01

  Provided herein are methods for the preparation of substituted pyrazino[2,3-b]pyrazines of the formula (II): the method comprising contacting a compound of formula (VI): with R1—Y in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R3, Y, the palladium catalyst and the base are as defined herein.

  本文提供了制备式 (II) 的取代吡嗪并[2,3-b]吡嗪的方法： 该方法包括与式 (VI) 的化合物接触： 在钯催化剂存在下，在溶剂中与 R1-Y 接触，其中所述接触是在碱存在下进行的，其中 R1-R3、Y、钯催化剂和碱如本文所定义。
• Treatment of cancer with TOR kinase inhibitors
  申请人：Signal Pharmaceuticals, LLC

  公开号：US11166950B2

  公开（公告）日：2021-11-09

  Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

  本文提供了治疗或预防患者实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的方法，包括向患有实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的患者施用有效量的TOR激酶抑制剂。
• INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US20140113905A1

  公开（公告）日：2014-04-24

  Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3β or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3β or p70S6K1.
• METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US20140314751A1

  公开（公告）日：2014-10-23

  Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.